Malissen N, Fabre C, Joujoux JM, Bourquard P, Dandurand M, Marque M, Stoebner P, Meunier L. [Multiple primary cutaneous plasmacytoma].
Ann Dermatol Venereol 2014;
141:364-8. [PMID:
24835649 DOI:
10.1016/j.annder.2014.01.003]
[Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2013] [Revised: 10/09/2013] [Accepted: 01/09/2014] [Indexed: 10/25/2022]
Abstract
BACKGROUND
Primary cutaneous plasmacytoma is a rare form of cutaneous B-cell lymphoma.
PATIENTS AND METHODS
A 51 year-old male with an unremarkable history gradually presented erythematous papulonodular lesions that had appeared gradually over the whole body throughout a two-year period and showing histologic and immunohistochemical features of cutaneous plasmacytoma. Staging investigations confirmed the primary character of the disease, and because of this and the absence of functional impairment, we opted for therapeutic abstention. No progression was noted after 4 years of regular monitoring.
DISCUSSION
Primary cutaneous plasmacytoma (PCP) is characterized by clonal proliferation of plasma cells in skin. Multiple PCPs are extremely rare and to date have been treated in most cases by chemotherapy, either with or without radiotherapy. The prognosis is poor, with 2-year survival of only 25%. The present case is original, being the only one to our knowledge in which therapeutic abstention was followed by a lack of progression after 4 years of regular follow-up. Consequently, certain indolent forms of PCP do not warrant automatic institution of chemotherapy.
Collapse